ODAC Veterans Disagree On Value Of Public Hearing At Panel Meetings
Executive Summary
Current and former chairs of FDA’s Oncologic Drugs Advisory Committee debate the usefulness of the public hearing and its impact on committee deliberations.
You may also be interested in...
From Avastin To Zevalin: ODAC’s Most Memorable Moments
The current and former leaders of FDA’s Oncologic Drugs Advisory Committee recount their most memorable moments of service on the panel.
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Tarceva Pancreatic Cancer Survival Merits Approval, More Study Of Dosing
Genentech/OSI should study sequential dosing of its epidermal growth factor receptor inhibitor Tarceva and Lilly's Gemzar, FDA and Oncologic Drugs Advisory Committee members suggested in recommending supplemental approval of erlotinib for treatment of pancreatic cancer Sept. 13